Posted on: May 30, 2024
Adults at high risk of severe outcomes due to COVID-19 are benefiting from access to nirmatrelvir-ritonavir (Paxlovid) as the Province provides 100% coverage for the drug.
Information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information.